Protalix BioTherapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Protalix BioTherapeutics, Inc.
Chiesi may not be a big pharma giant but it is very good at spotting early-stage innovative projects and partnering with the likes of Moderna, Protalix and Bioasis to tackle respiratory and rare diseases, CEO Ugo Di Francesco tells Scrip.
Keeping Track: US FDA Says Yes To AZ’s Farxiga In CKD And ADC’s Zynlonta, But No To Leo’s Tralokinumab, Chiesi’s Pegunigalsidase
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Shares in Protalix sank more than 30% after the company received a complete response letter from US regulators for pegunigalsidase alfa for Fabry disease. No inspection of the company's manufacturing plant in Israel appears to be the main sticking point.
Plus recent deals involving AbbVie/Caribou, Sanofi/i2O, Merck & Co./Starpharma, Protalix/SarcoMed, Targovax/Papyrus, Medivir/Ubiquigent, Eton/Azurity
- Large Molecule
- Synthesis Technologies, Production Processes
- Other Names / Subsidiaries
- Protalix Ltd.